Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis

NCT07006805 is registered in ClinicalTrials.gov with Cabaletta Bio as lead sponsor.

NCT NCT07006805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07006805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
RESET-MS: A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Participants With Multiple Sclerosis
Lead sponsor
Cabaletta Bio
Phase
Phase 1/2
Overall status
Withdrawn
Start date
June 30, 2026
Completion date
October 31, 2029
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis, multiple sclerosis (ms) - relapsing-remitting, multiple sclerosis (relapsing remitting), multiple sclerosis - relapsing remitting, progressive multiple sclerosis, progressive multiple sclerosis (pms), relapsing multiple sclerosis (rms)